


Single-cell multiplex approaches deeply map ON-target CRISPR-genotoxicity and reveal its mitigation by palbociclib and long-term engraftment

Received: 29 March 2025

Accepted: 17 December 2025

Published online: 10 January 2026

 Check for updates

Julian Boutin ^{1,2,9}, Sabrina Fayet^{1,9}, Victor Marin ^{1,2,9}, Camille Bergès ^{1,3,9}, Maude Riandière¹, Jérôme Toutain^{1,3}, Isabelle Lamrissi-Garcia¹, Chloé Thibault ¹, David Cappellen ^{1,4}, Sandrine Dabernat^{1,2}, Arthur Poulet ¹, Maëla Francillette⁵, Nathalie Droin ^{5,6}, Christelle Debeissat^{7,8}, Philippe Brunet de la Grange ^{7,8}, François Moreau-Gaudry ^{1,2,10} ✉ & Aurélie Bedel ^{1,2,10} ✉

Genome editing by CRISPR-Cas9-nuclease is promising for gene therapy. However, safety concerns remain. Monitoring ON-target genotoxicity is essential, especially to assay megabase rearrangements at the targeted *locus*. Here, we developed a combined single-cell resolution approach with DNA sequencing focused on single nucleotide polymorphism (scSNP-DNAseq), micronuclei and LOH cytometry-reporter assays. This sensitive multiplexed strategy enables the sensitive monitoring of CRISPR-mediated genotoxicity in primary cells. Using this approach, we detect, map and characterize various types of induced-losses of heterozygosity and assess editing-associated chromosomal instability. Importantly, palbociclib prevents the appearance of such genomic rearrangements in hematopoietic stem cells without impairing cell fate or graft capability. Conversely, short-term risk is significantly increased with DNA-PKcs inhibitor AZD7648. Fortunately, targeting *HBG1/2p*, scSNP-DNA-seq reveals that ON-target genotoxic events are no longer detectable after long-term xenografts. This work demonstrates that scSNP-DNA-seq should be routinely implemented to monitor chromosomal rearrangements before and after CRISPR-edited cell infusions.

CRISPR-Cas9 genome editing holds tremendous promise for gene therapy^{1–4}. It offers unprecedented potential for therapeutic applications. Numerous CRISPR-based clinical trials are ongoing and the first treatments are already approved for clinical use. Despite development

of new genome editing tools, most of current clinical applications still rely on CRISPR-Cas9 nuclease, and create a targeted DNA double-strand break (DSB). However, the repair of DSB can lead to complex and unpredictable outcomes, raising concerns about genotoxic risk

¹Univ Bordeaux, INSERM, UMR 1312, BRIC (Bordeaux Institute of Oncology), Bordeaux, France. ²CHU de Bordeaux, Biochemistry Laboratory, Bordeaux, France.

³CHU de Bordeaux, Medical Genetic Laboratory, Bordeaux, France. ⁴CHU de Bordeaux, Tumor Biology and Tumor Bank Laboratory, Bordeaux, France.

⁵INSERM US23, CNRS UAR 3655, AMMICA, Genomic Platform, Gustave Roussy Cancer Center, Villejuif, France. ⁶INSERM U1287, Gustave Roussy Cancer Center, Villejuif, France. ⁷Etablissement Français du Sang Nouvelle Aquitaine, Place Amélie Raba Léon, Bordeaux, France. ⁸Univ Bordeaux, Inserm Bordeaux UMR 1211 Rare Diseases, Genetics and Metabolism, Bordeaux, France. ⁹These authors contributed equally: Julian Boutin, Sabrina Fayet, Victor Marin, Camille Bergès. ¹⁰These authors jointly supervised this work: François Moreau-Gaudry, Aurélie Bedel. ✉ e-mail: francois.moreau-gaudry@u-bordeaux.fr;

aurelie.bedel@u-bordeaux.fr

and potential phenotypic alterations in edited cells. Both OFF-target and ON-target genotoxicity have been reported. ON-target genotoxicity includes various types of loss-of-heterozygosities (LOH): kilobase-scale interstitial copy-loss by deletions⁵ (CL-LOH), megabase-scale telomeric CL-LOH (truncations)⁶, and copy-neutral loss-of-heterozygosity (CN-LOH), which may lead to imprinting loss and disrupt imprinted genes expression⁷. Even larger genomic abnormalities have been observed, such as whole-chromosome loss⁸ and chromothripsis^{9–11}. Importantly, these genomic rearrangements are observed *in vitro*, a few days after editing, and have been observed in many cell types, in immortalized cell lines, adult primary cells, such as hematopoietic stem/progenitor cells (HSPCs) and CAR-T cells, and even in embryos^{8,12–14}.

p53 inhibitor¹⁵ and DNA-PKcs inhibitors (AZD7648)¹⁶ are being explored to improve homology-direct repair (HDR) efficiency. However, these DNA repair pathway modulations could exacerbate post-editing ON-target genotoxicity^{6,17,18}.

In this context, the clinical deployment of CRISPR-based therapies raises significant safety concerns that must be deciphered and addressed. The first published long-term data are encouraging. Indeed, CRISPR-induced aneuploidies in CAR-T cells seem to be mitigated by long-term culture *in vitro*⁸ and after graft in patients^{12,19}. In HSPCs, kilobase-scale genotoxicity following CRISPR targeting of *BCL11A* erythroid enhancers on chromosome 2 (Chr2) appears to diminish after 16-weeks post-graft in mice²⁰. However, whether extra-large (megabase-scale) ON-target genotoxicity persists long term *in vivo* and can be mitigated remains unknown.

Addressing these questions requires highly sensitive methods with single-cell resolution. Microfluidic single-cell-DNA sequencing (scDNA-seq) should be appropriate for analyzing the genome integrity, but its accuracy was challenged for a long time by the presence of only two genomic copies per cell. Hundreds of genomic *loci* can now be interrogated across thousands of cells. It is used to monitor intratumoral heterogeneity, clonal evolution, and residual disease in cancer^{21,22}. More recently, scDNA-seq revealed aneuploidies in human tumors²³.

Here, we propose a multi-assay approach to longitudinally evaluate ON-target genotoxicity induced by CRISPR-Cas9 in clinically relevant cells. We combined three orthogonal single-cell methods: (i) micronuclei (MN) detection, (ii) detection of LOH using our in-house Fluorescence-Assisted Megabase-scale Rearrangements Detection (FAMReD)¹⁷ assay, and (iii) scDNA-seq. Importantly, by gathering single-nucleotide polymorphism (SNP) and copy number variations (CNV) analyses, we demonstrate here that scSNP-DNAseq is a powerful assay to measure chromosomal instability following CRISPR editing, in particular CN-LOHs with high sensitivity, *in vitro* and *in vivo*.

Our orthogonal approach offers a sensitive and robust platform for assessing genome integrity of CRISPR-edited cells and ON-target genotoxicity. It enables us to precisely detect chromosomal instability, to map outcomes in human primary cells *in vitro*, to monitor its persistence *in vivo* after engraftment and to evaluate mitigation strategies.

Results

Design of the scSNP-DNAseq library and method validation for LOH quantification

To detect ON-target genotoxicity induced by CRISPR-Cas9, specifically kilobase- and megabase-scale LOH, either due to a deletion (copy-loss, CL-LOH) or without loss of genomic material (copy-neutral, CN-LOH), we designed a custom scDNA-seq library, focusing on SNPs in Chr10/Chr11 (Fig. 1a). We first identified SNPs common in the general population using the dbSNP database (NCBI, 150,000 SNPs) and filtered for those with global allele frequency more than 0.5 (15,000 SNPs), as well as those with high frequency in European and African populations (403 SNPs distributed along chr10/11, Fig. 1b). We then designed probes to

obtain 403 amplicons per cell containing the identified SNPs, with higher concentration near the CRISPR cut sites (Fig. 1b). We validated selected amplicons *in silico* with Bcftools on GIAB Coriell (NAI2878 v4.2.1). Amplicons on Chr10 served as control for CRISPR targeting of Chr11, and vice-versa. After CRISPR-Cas9-editing, each amplicon from each cell was sequenced to assess genome integrity. Loss of SNPs (genotyped in unedited control cells) was used to identify and map LOH presence in each cell.

For method validation, we created a positive control cell line with a 5Mb-terminal LOH on Chr10q (LOH⁺). This was achieved using our previously published FAMReD system¹⁷, based on human heterozygous *UROS*^{+/−} fibroblasts (hFFs) (Fig. 1c). By targeting *ABRAXAS2* by CRISPR nuclease, located 1Mb centromeric to the *UROS* locus in Chr10q, we observed a slight increase in the proportion of fluorescent cells 15 days post-editing (0.1–0.2%), suggesting the occurrence of rare LOHs events at *UROS* locus, leading to the loss of the functional *UROS*⁺ allele, and subsequent porphyrins accumulation. We then sorted and amplified the fluorescent cells (Fig. 1c), and analyzed them using scSNP-DNAseq with Mosaic 3.0 software. We identified SNPs located along Chr10q and selected five well-sequenced SNPs in *UROS*^{+/−} hFFs before editing (Fig. 1c). scSNP-DNAseq confirmed the disappearance of SNP3/4/5 and the presence of only 1 LOH profile (LOH10q1 with homozygous terminal profile) in fluo+ cells (pink). As expected, more than 99% of cells exhibited an extra-large LOH extending from the CRISPR cut-site (*ABRAXAS2*) to the telomere. We identified a unique LOH event, linked to the allele carrying the *UROS* mutation (LOH10q1), thereby validating the method at the allele level (Fig. 1d, e). Importantly, the non-targeted Chr11 remained fully heterozygous (yellow), with no SNP loss.

scSNP-DNAseq and global UMAP reveals frequent ON-target genotoxicity after double-cut in *HBG1/2* promoters in HSPCs

To investigate CRISPR-induced ON-target genotoxicity in human HSPCs, we edited the cells with the gRNA-68, which targets the two *HBG1/2* promoters, as previously reported by Sharma et al.²⁴. This protocol is known to predominantly induce 5kb-deletion between the two CRISPR-induced cut sites. We confirmed editing efficiency by long-range PCR and NGS analysis (Nanopore sequencing, Supplementary Fig. 1a). In parallel, we performed scSNP-DNAseq (Fig. 2a). First, we established the initial SNP profile in the unedited HSPCs. Using principal component analysis (PCA) and UMAP, we clustered 5161 edited cells, considering all SNPs, revealing three distinct populations based on 8 components and 88 detected SNPs (Fig. 2b). The majority of the cells (orange in UMAP) (Fig. 2b left) were heterozygous for all sequenced SNPs (Htz = A/B, white in the heatmap, right panel). UMAP analysis revealed two equally sized minor populations (2.4% and 2.2%, red and green, respectively). In these cells, 18 SNPs located between the *HBG1/2p* cut sites and the Chr11p telomere were lost and became homozygous (either A/A or B/B, indicated by pink or blue, respectively, Fig. 2b right), mapping an extra-large LOH (~5 Mb). These abnormal cells were classified as LOH11pI and LOH11pII, respectively.

To classify these LOHs as either copy-neutral (CN-LOH) or copy-loss (CL-LOH), we analyzed amplicon read-depth using the Mission Bio Mosaic pipeline to infer CNVs. Ploidy was calculated for each amplicon and cell exhibiting LOH by normalizing read counts against the mean of read counts of the “normal/orange” cell population. We observed abnormal ploidy at the chr11p extremity in both LOH populations (LOH11pI and LOH11pII, Fig. 2c left). Notably, genomic area with reduced ploidy (indicated in blue in the heatmap) corresponded to extra-large LOH events spanning from the cut site to the telomere. LOH ploidy was estimated by averaging the ploidy of amplicons within the LOH genomic region for each cell in both LOH populations (red and green). Ploidy in the LOH area was reduced: 1.28 and 1.22 for LOH11pI and LOH11pII, respectively (Fig. 2c right) compared to a ploidy of around 2 (normal) in the centromeric region of 11p and 11q arm, and




Fig. 1 | scSNP-DNAseq design to assay CRISPR-induced ON-target genotoxicity in chromosomes 10 and 11 (Chr10/11), and method validation for LOH quantification. **a** Design of home-made scSNP-DNAseq library in Chr10/11 focusing on frequent SNPs. **b** Mapping of amplicon densities around *ABRAXAS2*, *UROS* and *HBG1/2p* breakpoints. **c** Method validation using hFAMRed system. Heterozygous *UROS*^{+/-} hFFs switched from non-fluorescent to fluorescent in case of CRISPR-induced Chr10q telomeric LOH encompassing *UROS*. Chr10 is represented with

ABRAXAS2 and the five SNPs used to detect LOHs by scDNA-seq. *ABRAXAS2* targeting by CRISPR-Cas9 induced fluorescent cells 15 days after editing (0.1–0.2%). Fluorescent cells were sorted and cultured for 2 months to obtain enough cells before analysis by scSNP-DNAseq and Mosaic 3 software. **d** Histogram of SNP profiles in unedited/edited fluorescent hFFs (fluo+). **e** different SNP profiles identified by scSNP-DNA seq (WT, LOH 10ql, LOH 10qlI). Created in BioRender. Bedel, A. (2025) <https://BioRender.com/3fwjwd9>.

the control chr10. Copy-loss LOHs would be expected to show a ploidy of 1. These results suggest a mixture of CN-LOH and CL-LOH events. In summary, UMAP-based SNP analysis revealed significant ON-target genotoxicity following *HBG1/2p* targeting by CRISPR, with 4.6% of HSPCs exhibiting megabase-scale terminal LOH on Chr11p, the majority of which were terminal deletions (~70%).

scSNP-DNAseq focused on high-quality SNP confirms terminal copy-loss LOH and reveals interstitial LOH in HSPCs

To further explore in-depth megabase-scale LOHs (5 Mb), we reanalyzed the same edited cells, focusing on five high-quality SNPs along the targeted chr11 (selected from the 88 SNPs previously identified), each with a high genotype call rate (>60% of cells) (SNP1-5, megabase panel, Fig. 3a–c). Using this refined method, SNP profile clustering revealed a substantial percentage of cells (7.4%) exhibiting loss of the

SNP 3–5, located between the *HBG1/2p* cut sites and the 11p telomere. This finding confirms the presence of the two distinct telomeric LOHs (LOH11pI and LOH11pII) in HSPCs 4 days after transfection (D4, Fig. 3b, c). This method corroborates the global genotoxicity patterns identified via UMAP-based clustering. Yet it demonstrates increased sensitivity and highlights a higher frequency of chromosomal rearrangements (7.4 vs 4.6%).

Thanks to this increased resolution, we hypothesized that smaller, kilobase-scale LOHs may be present but undetected by UMAP analysis. We then looked for smaller interstitial LOHs in the same edited cells. To test this, we substitute SNP3 and SNP4, located 0.3 and 2.8 Mb from the CRISPR cut sites) with SNP6 and SNP7, positioned closer to the cut sites, (12 and 13.6 kb respectively (Fig. 3d and h, kilobasic panel). Clustering based on this kilobase-resolution panel identified, in addition to previously characterized terminal LOH ($n = 129$), two additional




Fig. 2 | Global UMAP clustering and LOH detection following *HBG1/2* promoters targeting by scSNP-DNAseq in HSPCs. a Experimental workflow. *HBG1/2p* were targeted using CRISPR-Cas9 in HSPCs from cord blood (CB), followed by Nanopore sequencing, scDNA-seq on day 4, and a UMAP clustering of cells. **b** UMAP projection and SNP-based classification of single-cells. **Left panel**, UMAP representation of 5161 analyzed cells (99.47% retained), with three distinct profiles: no LOH (orange), LOH11pI (red), and LOH11pII (green). **Right panel**, Convolved heatmap displaying all heterozygous SNPs in cell population on chr11 diversity across groups. Orange cells from UMAP are heterozygous (white in the heatmap A/B) for all analyzed SNPs, whereas green and red cells from UMAP have lost heterozygosity (18 SNPs lost, pink (Hom A/A) or blue (Hom B/B) in the heatmap between the *HBG1/*

2p cut sites and the telomere). **c** Ploidy analyses of LOH events. Averages of read depth of each amplicon were calculated in non-rearranged cells (“WT”) and used as a reference for a ploidy of 2. **Left panel**, heatmap representation of CNV across samples, highlighting copy-loss LOH regions (blue). **Right panel**, cGH-like chromosomal copy number profiles for LOH11pI (red box) and LOH11pII (green box), showing a reduction in ploidy (respectively 1.28 and 1.22, mean) in the telomeric part of targeted Chr11 arm. The position of the DSB is indicated. The non-targeted Chr10 was used as a control. Ploidy in LOH genomic area was calculated by the mean ratio of read depth of amplicons in the LOH area of edited LOH cells to non-edited cells. Created in BioRender. Bedel, A. (2025) <https://BioRender.com/3fwjwd9>.

cell populations with new SNP profiles. Specifically, 2.2% of cells ($n = 38$) exhibited loss of SNP6-7 while retaining distal telomeric SNP5 (Fig. 3e and h), indicative of interstitial LOHs (iLOH11pI and iLOH11pII), equally distributed between maternal and paternal alleles. These interstitial events raised the total LOH frequency to approximately 9%.

No LOH were detected on the non-targeted Chr10, supporting the specificity of CRISPR-Cas9 induced genotoxicity.

To determine whether the observed LOH were due to copy number loss (CL) or copy-neutral (CN) events, we assessed CNVs in LOH-containing cells using the kilobasic SNP panel (Fig. 3f, g),




Fig. 3 | Genotoxicity analysis using high-quality SNP-amplicons revealed that *HBGI/2* promoter targeting by CRISPR induces a wide range of LOHs in HSPCs. **a** Experimental design. HSPCs from cord blood (CB) were transfected with Cas9 nuclease RNP and gRNA targeting *HBGI/2* promoters and scSNP-DNAseq was performed at day 4. Five high-quality SNPs along the Chr11 were chosen (megabasic SNP panel), SNP1 on the non-targeted region 11q, SNP2 in Chr11p between the centromere and the cut site *HBGI/2p* and SNP3-5 telomeric to the cut site at 0.3, 2.8, and 4.6 Mb. **b** Histogram represents the cell percentages with LOH at day 4 ($n = 1870$ cells). Presence of 3 LOH profiles (WT = no LOH, telomeric LOH11pI and LOH11pII with loss of SNP3-5 (red or blue allele respectively)). **c** Description of the Megabasic SNP panel and the different SNP profiles identified by sc-SNP-DNA seq (WT, LOH 11pI, LOH 11pII). **d** A novel set of SNPs was chosen using two interstitial

SNPs (6 and 7) on the telomeric side (kilobasic SNP panel). **e** scSNP-DNAseq and kilobasic SNP panel pipeline revealed the presence of 2 novel interstitial LOH profiles (iLOH). Histogram represents the % of cells with interstitial and telomeric LOH (iLOH and tLOH) at day 4 ($n = 1855$ cells). **f** Cumulative histogram of copy-neutral and copy-loss LOHs in each profile (number of cells indicated). **g** Ploidies and cGH-like representations (CNV analyses) along the targeted Chr11 for the 5 profiles (WT, LOH11pI, LOH 11pII, iLOH11pI, and iLOH11pII), and of the non-targeted Chr10 (negative control). Ploidy in LOH genomic area was calculated by the mean ratio of read depth of amplicons in the LOH area of edited LOH cells to non-edited cells. **h** Different SNP profiles identified by sc-SNP-DNA seq and kilobasic SNP panel pipeline (WT = no LOH), LOH 11pI, LOH 11pII, iLOH 11pI, iLOH 11pII). Created in BioRender. Bedel, A. (2025) <https://BioRender.com/3fwjwd9>.

considering all amplicons. LOH ploidy was estimated by the average of amplicon ploidies across the LOH region for each cell in each population. Among the 1855 analyzed cells, 129 cells exhibit a terminal 11p LOH. In these cells (LOH11pI and LOH11pII), the calculated mean LOH ploidies were 1.25 and 1.18, respectively, suggesting that ~80% of these LOHs resulted from terminal deletions (Fig. 3f, day 4). In the 38 cells with interstitial LOHs (iLOH11pI and iLOH11pII), mean ploidies in the

affected 43 kb LOH area (from the cut site to *AC104389.16*), were 1.44 and 1.21, respectively, again indicating a predominance of interstitial deletions (Fig. 3g). Altogether, we demonstrated the value of high-quality SNP-focused scDNA-seq for deciphering and precisely mapping the ON-target genotoxicity of *HBGI/2p* targeting by CRISPR-Cas9 in primary cells. Our data revealed a high frequency of both interstitial and terminal deletions at day 4.

AZD7648 increases short-term genotoxicity in human fibroblasts

Pharmacological modulators known as “HDR boosters” have been proposed to improve the HDR rate during CRISPR-mediated genome editing. To evaluate the impact of three HDR boosters on editing efficiency and genotoxicity, we treated hFFs with XL413, an inhibitor of CDC7, and two DNA-PKcs inhibitors, NU7441 and AZD7648, during *ABRAXAS2* editing with a high-fidelity (HiFi) Cas9, and a single-strand oligo-desoxy ribonucleotide (ssODN) template to obtain HDR (Fig. 4a). We monitored ON-target genotoxicity by a multiplex single-cell method approach combining MN assays, cytometry-based LOH detection, and scSNP-DNAseq.

PCR and Sanger sequencing revealed that, among these tested compounds, only AZD7648 significantly increases the HDR/NHEJ ratio in hFFs (Supplementary Fig. S2a, b). The “HDR boosters” genotoxicity was first assessed using a cytometry-based MN assay at day 4 post-editing (Fig. 4b left panel). AZD7648 treatment markedly elevated MN formation after *ABRAXAS2* editing (up to 0.7% of MN/nucleus vs 0.16% in edited hFFs without AZD7648, Fig. 4b), indicating increased genotoxic stress.

To confirm this result, we edited hFFs at *HBG1/2p* loci. Once again, an increase of MN was observed in the presence of AZD7648 (Supplementary Fig. 2d), without any change in editing efficiency as measured by nanopore sequencing (Supplementary Fig. 2c). The FAMReD system, developed in our lab to sensitively detect telomeric LOH by cytometry following CRISPR-Cas9 editing, confirmed the genotoxicity of AZD7648 in hFFs and showed persistence of megabase-scale terminal LOH at day 18 (0.6% of fluorescent LOH⁺ cells vs 0.16% in DMSO control) (Fig. 4b right panel). Since FAMReD detects only 50% of the events, the true long-term LOH frequency is double (1.2% of edited cells treated with AZD7648). A smaller genotoxic effect was observed with Nu7441 (by both MN and FAMReD analyses). The effect of AZD7648 was exacerbated in *TP53*^{-/-} hFFs (Supplementary Fig. 2e left, 6% of cells with telomeric LOH).

To quantify, map, and characterize the nature of post-editing LOH events in the presence or absence of AZD7648, the most genotoxic HDR booster, we performed a kinetic analysis of ON-target genotoxicity using scSNP-DNAseq analysis, before and after hFFs editing at *ABRAXAS2* locus, with a ssODN template, with or without AZD7648 (Fig. 4a, Days 2-7-20). Bioinformatic analysis first identified five informative SNPs in non-edited cells, selected with stringent quality criteria to enable megabase-scale resolution. After editing, clustering based on these five SNPs revealed four cell populations with distinct SNP profiles (Supplementary Fig. 3a): one population with heterozygous SNPs along the Chr10 (“WT”), two abnormal populations with allele loss for 3 SNPs 3/4/5, from each parental chromosome (designated telomeric “LOH10qI” and “LOH10qII”), and a fourth abnormal population showing loss of all analyzed SNP (Chr10pq SNP loss).

After editing in hFFs without AZD7648, we observed, on day 2, 1.5% of cells with telomeric 10q LOH, extending from the cut site to the telomere (Fig. 4c left panel D2), and rare cells with complete loss of SNPs. CNVs analysis, performed only when more than five cells were available per population, revealed reduced ploidy in both LOH10qI and LOH10qII populations (1.07 and 1.37 in LOH10qI and LOH10qII respectively), demonstrating that most LOH events were due to genomic material loss (93% and 63% of deletions (CL-LOH), in LOH10qI and LOH10qII respectively, Fig. 4c left panel D2). The high rate of telomeric LOH persisted at day 7 (in 1.9% of cells) (Fig. 4c left panel), with a balanced mix of CN-LOH and CL-LOH (ploidy 1.69 et 1.59). Interestingly, in the same edited cells, the frequency of LOH dropped clearly by day 20 (0.23%).

Unexpectedly, in the presence of AZD7648, no LOH was detected on day 2 using scSNP-DNAseq (Fig. 4c right panel). We hypothesized that DNA-PKcs inhibition during a DSB induction might slow down cell division, delaying the onset of ON-target genotoxicity. We therefore

analyzed the cell cycle of hFFs exposed to AZD7648. When a DSB occurs concomitantly with AZD7648 treatment, hFFs tend to accumulate in the G0 phase at day 2 (Supplementary Fig. 3b). These results may explain the absence of detectable LOH immediately after editing. At day 7, however, a high rate of LOH was observed (3.9% of cells), with a mixture of CN-LOH and CL-LOH (ploidy 1.31 et 1.48 in LOH10qI and LOH10qII respectively). This genotoxicity was partially maintained at day 20 (1.37%), suggesting a delayed onset and sustained maintenance, compared to without AZD7648. At day 20, in the presence of AZD7648, the persistent LOHs were predominantly copy-neutral (ploidy 1.68 and 1.59 in LOH10qI and LOH10qII respectively, Fig. 4c right panel). “cGH like” schematic representations are provided in Supplementary Fig. 4. No LOH was detected on the non-targeted Chr11.

Among all tested HDR enhancers, AZD7648 reached the highest short-term genotoxicity in hFFs. Kinetic reveals that LOHs, initially resulting from DSB and chromosomal truncations, tend to convert into copy-neutral LOHs and diminish in frequency at day 20.

AZD7648 increases short-term ON-target genotoxicity in HSPCs targeting *UROS* (Chr10q)

Because DNA repair pathways are cell-type dependent, we next investigated the genotoxicity of HDR boosters in HSPCs (Fig. 4d). We targeted the *UROS* locus in Chr10q in the presence or absence of HDR boosters. PCR and Sanger sequencing confirmed an increase in the HDR rate upon AZD7648 treatment (77% vs 12%, Supplementary Fig. 5a). Again, AZD7648 exposure during editing led to a dramatic increase in MN formation (up to 3–4% of MN/nucleus), suggesting that modulating DNA repair pathways during DSB repair also elevates genotoxicity in HSPCs (Fig. 4e and illustrative Supplementary Fig. 5b). DNA staining by DAPI and fluorescence microscopy of edited HSPCs further confirmed the increase in nuclear abnormalities upon AZD7648 treatment (Supplementary Fig. 5c).

To monitor the kinetics of unwanted genome editing outcomes in HSPCs, we designed a time-course scSNP-DNAseq analysis with or without AZD7648. HSPCs were edited, cultured, and collected on days 4, 7, and 14 for scSNP-DNAseq. We identified four cell populations post-editing: “WT” without LOH (all SNP heterozygous), telomeric LOHs “LOH 10qI” and “LOH 10qII” (SNPs 3/4/5 loss), and whole-chromosome LOH “LOH 10pq” (all SNPs lost) (Supplementary Fig. 5d). Without AZD7648, CRISPR editing led to 2–4% of rearranged cells, mostly showing telomeric LOHs (“LOH 10qI and LOH 10qII”, Fig. 4f left) from day 4 to day 14, confirming that even a single DSB can induce ON-target genotoxicity. AZD7648 exposure significantly increased the proportion of cells with telomeric LOHs throughout the time-course (day 4 to day 14), reaching ~7%, a threefold increase compared to CRISPR alone (Fig. 4f right). These results indicate that telomeric LOHs are stable in vitro over a two-week period. No LOH was detected on the non-targeted Chr11, even with AZD7648. Under all conditions, with or without AZD7648, and whatever the time point, the majority of LOHs were copy-neutral, with ploidy values around 2 (ranging from 1.74 to 2, Fig. 4f). The whole-chromosome ploidy patterns “cGH-like” are shown in Supplementary Fig. 6.

Taken together, these data demonstrate that AZD7648 induces both short- and medium-term ON-target genotoxicity in HSPCs, with immediate cellular stress (MN and nuclear abnormality formations) and the persistence of extra-large copy-neutral LOH events in vitro for up to two weeks.

Palbociclib prevents post-editing ON-target genotoxicity in HSPCs

Mitigating ON-target genotoxicity is essential for the safe development of CRISPR-based gene therapy using nucleases. DSB-induced large-scale genotoxicity is thought to mainly occur in dividing cells. We hypothesized that G0/G1 cell cycle arrest could mitigate chromosomal rearrangements observed in HSPCs (Figs. 2–4d, e). In a previous work, we demonstrated that palbociclib, a CDK4/6 inhibitor, effectively




Fig. 4 | Time course of AZD7648 short-term megabase-scale genotoxicity in hFFs and HSPCs. **a** Experimental design. hFFs were transfected with Cas9 RNP, ssODN template and gRNA targeting *ABRAXAS2*, with or without HDR boosters (AZD7648, red; 1 µM; NU7441, orange; 2.5 µM; XL413, green; 20 µM; DMSO control, blue). Schema of the Chr10 and analyzed SNPs. Cell cycle phases (day 2), micronuclei count (day 4), editing efficacy (day 7), LOH detection by FAMReD (day 18), and scSNP-DNAseq kinetic were performed. **b** **Left panel**, % of micronuclei (MN) quantified by cytometry (Mean ± SD, $n = 5$ independent experiments, One-way ANOVA test (two-tailed)). **Right panel**, % of fluorescent cells induced by *ABRAXAS2* editing at day 18 using the FAMReD system. Fluorescent cells are due to telomeric megabase-scale LOH (Mean ± SD, $n = 4$ independent experiments, One-way ANOVA test (two-tailed)). **c** 5 high-quality SNPs along the Chr10, present in unedited cells, were selected. % of LOH in hFFs detected by scSNP-DNAseq at day 2, 7, and 20, with

or without CRISPR-Cas9 and AZD7648 (right histogram with AZD7648, Chi-square test (two-tailed)). Number of cells exhibiting LOH10pI and LOH10pII profiles, ploidy, and % of copy-loss LOH. **d** Experimental design. HSPCs were transfected with Cas9 RNP, ssODN template, and gRNA targeting *UROS*, with/without AZD7648. Schema of the Chr10 and analyzed SNPs. Micronuclei count (day 2), editing efficacy (day 7), and scSNP-DNAseq kinetic were performed. **e** Histogram with % of MN after HSPCs editing (Mean ± SD, $n = 3$ independent experiments, One-way ANOVA test (two-tailed)). **f** 5 high-quality SNPs along the Chr10, identified in unedited cells, were selected (megabase panel). % of LOH in HSPCs by scSNP-DNAseq at day 4, 7, and 14 after transfection, with/without CRISPR-Cas9 and AZD7648 (right histogram, Chi-square test (two-tailed)). Number of cells exhibiting LOH10pI and LOH10pII profiles, ploidy, and % of copy-loss LOH. Created in BioRender. Bedel, A. (2025) <https://BioRender.com/3fwjw9d>.

blocks fibroblasts in the G0/G1 phases¹⁷. We therefore investigated whether palbociclib could transiently arrest HSPCs in G0/G1 during editing and thereby prevent genotoxicity in clinically relevant human HSPCs.

We first monitored its impact on (i) HSPCs cell cycle progression, (ii) editing efficiency (*via* long-range PCR and nanopore sequencing), and (iii) genotoxicity using multiplexing single-cell approaches (MN and scSNP-DNAseq) (Experimental design, Fig. 5a). We optimized the




Fig. 5 | Palbociclib prevents genotoxicity in HSPCs. a Experimental design. HSPCs from CB were edited with Cas9 RNP and gRNA targeting *HBG1/2* promoters with or without palbociclib exposure (1 μM, overnight before transfection and for 24 h or 48 h post-transfection). Cell cycle analysis, nuclear abnormalities, and micronuclei count (day 2), Nanopore sequencing, and scSNP-DNAseq (day 4) were performed. **b** Histogram of cell cycle after 12 h and 36 h of cell culture with or without palbociclib (Mean ± SD, $n = 3$ independent experiments), and after 48 h of clearance. **c Left panel**, fluorescence microscopy: % of nuclear abnormalities quantified by DAPI staining at day 2 (Mean ± SD, $n = 3$ independent experiments,

with 300, 100, and 100 cells, respectively). Paired t -test (two-tailed)). **Right panel**, % of micronuclei (MN) quantified by cytometry at day 2 (Mean ± SD, $n = 3$ independent experiments). One-way ANOVA test (two-tailed), at least 10,000 analyzed cells per condition). **d** % of LOHs (interstitial and terminal) quantified by scSNP-DNAseq (using 5 high-quality SNPs, kilobasic panel in Supplementary Fig. 3f) at day 4 without/with palbociclib exposure. Histogram represents the % of interstitial and telomeric LOH (iLOH in pink and light blue, and tLOH in red and blue). Percentages of LOHs in HSPCs were compared by the Chi-square test (two-tailed). Created in BioRender. Bedel, A. (2025) <https://BioRender.com/3fvjwd9>.

dose and timing of palbociclib to transiently block HSPCs in the G0/G1 phases (Fig. 5b and illustrative Supplementary Fig. 7a). Just after thawing, nearly all HSPCs were in G0/G1 phases (99%). While this proportion decreased after 12 h in culture, palbociclib maintained a higher fraction of cells in G0/G1 (84% vs 63% without palbociclib). A 36 h-palbociclib exposure further enhanced this effect (92% of cells in G0/G1 phase vs 70% without palbociclib), which was reversed upon drug removal (81% G0/G1 cells with palbociclib after 36 h-treatment and a 48h-clearance/washout vs. 76% in untreated cells, Fig. 5b). For comparison, cytokine starvation was also tested to reduce cell

proliferation (Supplementary Fig. 7b–d). Comparison between palbociclib vs cytokine starvation revealed that palbociclib was more efficient than 3 ng/mL cytokine starvation to synchronize the cells (Supplementary Fig. 7b 36 h). Complete cytokine starvation (0 ng/mL) is equally potent to palbociclib to arrest the cells in G0/G1 (Supplementary Fig. 7b 36 h) and block proliferation (Supplementary Fig. 7c) but more toxic (Supplementary Fig. 7d). Thus, palbociclib was selected for transient HSPCs cell cycle arrest in the remainder of the study.

We then edited *HBG1/2p* in HSPCs in the presence of palbociclib. Treatment during editing maintained >95% of cells in G0/G1 phases

(Fig. 5b) without compromising editing efficiency (Supplementary Fig. 1).

To evaluate short-term ON-target genotoxicity, we first analyzed nuclear abnormalities in HSPCs at day 2 by DAPI staining (MN, nuclear buds...). Fluorescence microscopy revealed that CRISPR targeting of *HBG1/2p* induced a high rate of abnormal nucleus, hallmarks of genomic instability (around 20% of cells with abnormal nucleus, Fig. 5c left, blue). Palbociclib reduced this frequency by more than twofold (Fig. 5c left, green).

To confirm, we performed MN analysis by cytometry. *HBG1/2p* targeting by CRISPR led to a high MN rate (Fig. 5c right, blue), which was again reduced over twofold with palbociclib in HSPCs (from 1.8% to 0.9%, Fig. 5c right, green).

To track chromosomal rearrangements, we collected cells on day 4 to perform scSNP-DNAseq using the kilobasic panel described in Fig. 3h (Fig. 5d). Total LOH frequency (telomeric + kilobasic) dropped from 9.2% in edited controls to 2.9% or 2.1%, with 24 h or 48 h of palbociclib exposure, respectively. These data demonstrate that 24-h exposure to palbociclib is sufficient to protect HSPCs from ON-target genotoxicity. In the remaining rearranged cells, all four LOH subtypes were still present, but palbociclib altered their distribution. Specifically, telomeric LOH frequency dropped from 6.95% to 1% after 48 h of palbociclib treatment, a sevenfold reduction, while interstitial LOH frequency was only reduced twofold (from 2.25% to 1.1%, Fig. 5d). Ploidy analysis of each LOH event ("cGH like" patterns, Supplementary Fig. 8) showed that the proportion of CL-LOH and CN-LOH was unchanged after 24 h of palbociclib (ploidy -1.3, corresponding to 70% deletions in both conditions). Altogether, these findings demonstrate that transient G0/G1 arrest by palbociclib (12 h pre-treatment + 24 h post-editing exposure) effectively protects HSPCs from DSB-induced damages (preferentially megabase-scale LOH), without compromising editing efficiency via NHEJ.

We hypothesized that G0/G1 maintenance by palbociclib may prevent genotoxicity by promoting end-joining. Because MMEJ is absent in G0/G1, we challenged NHEJ implication in palbociclib preventing effect. To test this, we used the highly sensitive FAMReD system to evaluate the effect of concomitant NHEJ inhibition by AZD7648 during palbociclib exposure (Supplementary Fig. 9). Interestingly, in the presence of AZD7848 plus palbociclib, megabase LOH rate was exacerbated (Supplementary Fig. 9b). However, cell cycle analysis showed that cells remained synchronized in G0/G1 (Supplementary Fig. 9a). These data demonstrate that the protective effect of palbociclib relies on NHEJ activity to prevent megabase-scale chromosomal rearrangements. Sequencing data further support the NHEJ importance in palbociclib-treated cells with an increase of small indels proportion (Supplementary Fig. 9c).

Palbociclib improves cell graft capability and hematopoietic reconstitution of HSPCs

By inducing G0/G1 cell cycle arrest in HSPCs, palbociclib could theoretically impair cell proliferation and impact in vitro/in vivo hematopoietic function (Fig. 6a). We first carried out an in vitro test of proliferation. As expected, palbociclib transiently reduced HSPCs proliferation in hematopoietic liquid culture (Fig. 6b), similar to complete cytokine starvation (0 ng/mL, red line, Supplementary Fig. 7c) but with less toxicity (0 ng/mL, 53.5% of alive cells vs 69% using palbociclib and even 78% using palbociclib in edited cells, Supplementary Fig. 7d).

This proliferation slow-down could affect in vivo HSPCs properties. To assess longer-term consequences, we grafted equivalent numbers of HSPCs pre-treated or not with palbociclib into NOD-*scid* IL2R γ null (NSG) mice (experimental design Fig. 6a). After 17 weeks post-transplantation, bone marrow (BM) chimerism (% hCD45⁺ cells) was higher in mice receiving palbociclib-treated cells (Fig. 6c left). Hematopoietic lineage reconstitution (hCD33⁺ and hCD19⁺ cells) in BM was comparable between conditions,

demonstrating that palbociclib does not impair multilineage differentiation (Fig. 6c, middle and right panels).

To quantify grafting capacity, we performed limiting dilution analysis (LDA) across 120 mice (Fig. 6d). LDA confirmed that palbociclib does not compromise HSPCs engraftment and even enhances it. Indeed, the number of transplanted mice is greater with palbociclib than without. For example, among mice transplanted with 100 and 500 cells, only those incubated with palbociclib show successful engraftment (2/20 vs 0/20 mice, Fig. 6d). This result was confirmed in secondary recipient mice, with a higher number of engrafted mice in the palbociclib group (4/10 vs 2/10, Fig. 6d). The frequency of SCID Repopulating Cells (SRCs) was 2.6-fold higher with palbociclib (1/1360, CI [1/740-1/2500]), compared to untreated controls (1/3541, CI [1/1700-1/7350]).

These findings suggest that, by forcing HSPCs to be in the G0/G1 phases, palbociclib could modulate their stemness properties. Phenotypic analysis after 36 h of exposure showed an increased frequency of stem cell population (CD34⁺/CD38^{low}/CD90⁺/CD133⁺) (from 12% to 26%, Fig. 6e), suggesting the maintenance or selection of stem cells, or possible progenitor dedifferentiation. This is supported by the upregulation of hematopoietic stemness-associated genes such as *CXCR4*, *TALI*, and *RUNX1* in HSPCs treated with palbociclib for 36 h (Fig. 6f).

To confirm the palbociclib's positive effect on engraftment in context of nuclease-based genome editing, we targeted *ABRAXAS2* locus in HSPCs, with or without palbociclib exposure (12 h pre-treatment + 24 h post-editing). Editing efficiencies were very high in both conditions (Fig. 6g). Following palbociclib removal, equal numbers of cells were transplanted into NSG mice. Again, chimerism was higher in the palbociclib group (Fig. 6h left), without altering CD19⁺ and CD33⁺ lineage distribution (Fig. 6h, middle and right panels). Together, these results demonstrate that palbociclib is not deleterious, and in fact enhances HSPCs engraftment. Its use during CRISPR protocols could therefore be explored as a strategy to prevent ON-target genotoxicity while preserving or enhancing edited-HSPCs transplantation.

Chromosomal rearrangements disappear after long-term engraftment

To evaluate longer-term impact of LOH events on HSPCs proliferation and function, we engrafted CRISPR-edited HSPCs (targeting in *HBG1/2p*) into NSG mice for in vivo genotoxicity monitoring (Fig. 7a). Prior graft, we confirmed editing efficiency (Fig. 7b). In parallel, we observed the immediate genotoxicity by MN assay (Fig. 7c and Supplementary Fig. 10).

We grafted 400,000 edited human HSPCs per mouse, 24 h after CRISPR editing, with or without AZD7648 exposure ($n=2$ mice per condition). We then analyzed LOH frequency by scSNP-DNAseq in "before graft" and 3 months after graft (in vivo) to assess persistence of genotoxicity in BM HSPCs (Fig. 7a). For that, we harvested BM cells from mice 90 days after graft. We obtained high chimerism (hCD45⁺ cells) highlighting a good hematopoietic reconstitution (Fig. 7d). Human hematopoietic CD45⁺ cells were sorted by magnetic beads and purity confirmed before scSNP-DNAseq analysis. Before graft, 3.6% and 10.5% of cells exhibited megabase-scale telomeric LOH (from *HBG1/2p* to the 11p telomere) in the absence or presence of AZD7648, respectively (Fig. 7e, f). However, at day 90 post-engraftment, no genotoxicity was detected, even though edited alleles persisted (Fig. 7b, day 90). These findings demonstrate the complete disappearance of rearranged cells over time in vivo, including in the more genotoxic AZD7648 condition.

To sum up, these data establish that scDNA seq can be used to monitor in vivo ON-target genotoxicity and show that Chr11p LOH⁺ cells do not persist in vivo, even after editing with AZD7648.

Discussion

Genotoxicity is a major concern for innovative therapeutic approaches involving genome editing. To address this, we




Fig. 6 | Palbociclib effect on HSPCs phenotype and graft capability.

a Experimental design. HSPCs from CB, edited or not in *ABRAXAS2*, were cultured \pm palbociclib exposure (1 μ M, medium with 100 ng/mL cytokines, 36 h after transfection). Proliferation, phenotype (surface markers and stemness gene expression) and long-term engraftment in NSG mice were performed. **b** Proliferation assay by cell count, \pm palbociclib added during the first 36 h (Mean \pm SD, $n = 3$ independent experiments). **c** Analysis of BM cells 17 weeks after engraftment. Chimerism (% of hCD45⁺ cells), % of hCD33⁺ and hCD19⁺ cells in the BM of engrafted mice after injection of 10000 cells, pre-incubated \pm palbociclib (1 μ M, 36 h) (Mean \pm SEM, $n = 10$ mice per group, Wilcoxon matched-pairs signed-rank test (two-tailed)) at week 17. **d** Limiting dilution assay (LDA) in NSG mice ($n = 120$). A scale from 25 to 3000 cells, pre-incubated with/without palbociclib (1 μ M, 36 h) were IV-injected and engraftment was evaluated at week 17 by hCD45⁺ chimerism in femurs. BM (1 femur) of mice engrafted with 3000 cells sorted were re-injected in secondary

mice. Positive engraftment was considered when hCD45⁺ was >0.1%. **e** Cell surface marker analysis (CD34/CD38/CD90/CD133) by cytometry to evaluate hematopoietic stem population, at thawing (H0), 36 h after cell culture with/without palbociclib (Mean \pm SD, $n = 3$ independent experiments). **f** Hematopoietic stemness gene expressions by RTqPCR. Results are normalized on expression in HSPCs at thawing (H0) (mean \pm SD, $n = 3$ independent experiments, Two-way ANOVA followed by Tukey's multiple comparisons (two-tailed) test). **g** Editing efficiency at day 7 evaluated by sanger sequencing and DECODR software (mean \pm SD, $n = 3$ independent experiments). **h** Analysis of hematopoietic reconstitution in NSG mice 17 weeks after engraftment of *ABRAXAS2*-edited cells, with/without palbociclib. BM from femur was analyzed (% hCD45⁺, hCD33⁺, and hCD19⁺) (Mean \pm SEM, $n = 10$ mice, Mann-Whitney *U* tests with FDR correction for multiple comparisons (two-tailed)). Created in BioRender. Bedel, A. (2025) <https://BioRender.com/3fwjwd9>.

developed a multiplex single-cell approach that combines innovative scSNP-DNAseq with a micronucleus and a LOH cytometry-reporter assays. By combining CNV analysis and high-quality SNPs amplicon sequencing, our in-house approach enabled sensitive

detection, quantification, and classification of ON-target LOH as either deletion-based or copy-neutral. Indeed, in case of LOH, heterozygous SNPs are lost and are easily detected by sequence modification.




Fig. 7 | Long-term in vivo genotoxicity assessment of *HBG1/2p* editing protocol, with or without AZD7648. a Experimental design. Human HSPCs cells from cord blood (CB) were transfected with Cas9 nuclease RNP and gRNA targeting *HBG1/2* promoters, with or without AZD7648. In vitro studies: micronuclei analysis (day 2), editing efficiency by Nanopore sequencing (day 4), and scSNP-DNAseq (day 4). In vivo study: Engraftment of 400,000 edited human HSPCs at day 2 in 4 NSG mice (2 with and 2 without AZD7648). BM harvesting, sorting of hCD45⁺ cells at day 90, editing efficiency by Nanopore sequencing, and scSNP-DNAseq analysis to assess long-term in vivo genotoxicity (day 90). **b** Long-range PCR and Nanopore sequencing of *HBG1/2* promoters from edited HSPCs. Histogram of % of WT, InDels, and deleted alleles. Double DSB in *HBG1p* and *HBG2p* mostly induces a 5kb deletion.

c % of micronuclei (MN) quantified by cytometry at day 2 (Mean ± SD, $n = 3$ independent experiments, One-way ANOVA test (two-tailed), at least 10,000 cells per condition) without grey) or with (red) AZD7648. **d** hCD45⁺ quantification by cytometry to measure BM mice chimerism analysis at week 17 and after hCD45⁺ cell enrichment. **e** scSNP-DNAseq at D4 (in vitro, short-term) and D90 (in vivo, long-term) with or without AZD7648 during editing. % of telomeric LOH are indicated. Percentages of LOHs in HSPCs were compared by the Chi-square test (two-tailed). **f** Description of the Megabase SNP panel and the different SNP profiles identified by sc-SNP-DNA seq (WT, LOH 11pI, LOH 11pII). Created in BioRender. Bedel, A. (2025) <https://BioRender.com/3fwjw9>.

This robust strategy enables high-resolution, and accurate longitudinal monitoring of editing-associated chromosomal instability in clinically relevant cells, both in vitro and in vivo. It provides precise detection, description, and mapping of ON-target genotoxicity at the single cell level.

Our approach is more accurate than previous genotoxicity assays (CGH/SNP-arrays, optical genome mapping, FISH, PCR...)

because (i) it relies on single cell analysis, more sensitive than bulk analyse, and because (ii) it focuses on SNP in DNA, rather than scRNAseq^{8,12}, highlighting heterogeneity of outcomes (kilobase- and megabase-scale) and revealing frequent copy-neutral LOHs. Very recently, the same approach, scDNAseq has been also applied to study OFF-target genotoxicity and associated translocations²⁵.

This approach was applied to human primary cells, fibroblasts, and HSPCs, with editing performed at multiple loci on chromosomes 10 and 11. The theoretical sensitivity of detection of genotoxic events is 0.1%. To ensure high confidence and filter for technical artifacts, we defined a genotoxic event as a recurrent SNP profile observed in at least four individual cells. With these criteria, to reach 0.1% sensitivity, detecting a rare LOH event requires high-quality sequencing of 4000 cells. In practice, by loading 75,000 to 100,000 cells in the Tapestry platform, we obtained around well-sequenced 3000 fibroblasts and well-sequenced 1000 HSPCs, leading to a sensitivity from 0.13 to 0.3%. This cell throughput is suitable for clinical applications.

scSNP-DNAseq generates a lot of data. We compared two bioinformatic pipelines to detect LOH: i) considering all the amplicons containing SNPs (global UMAP method Fig. 2), or ii) focusing on a set of five discriminant high-quality SNPs amplicons (SNP panel Fig. 3). We demonstrated that the second method, based on 5 discriminant SNPs is more performant than the global SNP approach.

Using this method, we identified heterogenous ON-target genotoxic outcomes reflecting the implication of several DSB repair pathways, and their dynamic time-course. Notably, genotoxicity in HSPCs was more severe when targeting *HBG1/2p* compared to *UROS*, showing higher frequency of both telomeric and interstitial LOHs, predominantly associated with deletions. This difference is likely due to DSBs occurring in two homologous sequences²⁴. In a previous study, targeting another site in *HBG1/2p* in HSPCs²⁶, we subcloned manually the edited cells and observed at day 30 large CN-LOHs after long-term amplification, associated with imprinting defects in *H19/IGF2* center⁷. Here, early analysis (day 4) revealed, in HSPCs, kilobase/megabase-scale deletions (5.2 Mb encompassing 169 genes) in addition to known copy-neutral events (CN-LOH) in HSPCs. This contrast highlights the dynamic evolution of genotoxicity profile in HSPCs and underscores the need for longitudinal monitoring. In this context, scSNP-DNAseq emerges as a powerful and innovative tool for early genotoxicity detection and monitoring.

Understanding CRISPR-Cas9 ON-target genotoxicity is essential to anticipate and prevent potential risks. Spontaneous LOHs occur infrequently in human cells (<0.01%)²⁷. The high frequency of in vitro CN/CL-LOH starting from the cut site, interstitial, or telomeric described in this work, is unlikely to be a random process. The diversity of genomic outcomes highlights the complexity of DSB repair. After DSB, NHEJ and homologous repair (HR) are the main mechanisms that resolve DSBs. In diploid cells, HR can result in interstitial copy-neutral LOH, either without or with cross-over. Alternatively, synthesis-dependent strand annealing SDSA (gene conversion) may create small interstitial copy-neutral LOHs. In case of chromosome truncations, the terminal chromosome-arm is lost by segregation errors during mitosis, inducing LOH associated with an extra-large deletion²⁸. In primary cells lacking telomerase activity, the loss of telomeric regions is particularly detrimental. However, recently, Jasin et al. reported that neo-telomere can be added²⁹. If a neo-telomere cannot be added, we hypothesize that such events could be rescued by a secondary duplication of the remaining allele through break-induced replication, resulting in a CN-LOH.

When CRISPR is used for gene knockout, the error-prone NHEJ serves well. However, for precise genome editing, NHEJ can hinder the HDR, thereby reducing editing accuracy. To enhance HDR rate, DNA repair modulators, commonly named HDR boosters, have been proposed. We assessed the genotoxic risk associated with XL413³⁰ and DNA-PKcs inhibitors (NU7441 and AZD7648), known to increase HDR^{31–33} or targeted integration^{34,35}. Our orthogonal approach revealed that AZD7648 poses a significant risk, as it induces megabase-scale ON-target genotoxicity in vitro, including a threefold increase in telomeric LOH and MN increases in two primary human cells, targeting distinct genomic loci. Notably, genotoxicity associated with AZD7648 was not detectable at day 2 but became detectable later, highlighting the

importance of delayed analysis. This observation aligns with a preprint from the Turchiano lab, which reported that NHEJ inhibition delays DSB repair³⁶ and are in favor of chromosomal missegregation³⁷. We hypothesized that, if Cas9-induced chromosomal DSBs are not repaired prior to mitosis, the resulting acentric telomeric fragments may missegregate, forming MN that can drive chromosomal instability⁹. By blocking rapid NHEJ-mediated chromosome end-joining at the DSBs, DNA-PKcs inhibition likely increases the persistence of unrepaired DSBs, disrupting proper end pairing and elevating the risk of chromosomal truncations and long-term extra-large LOH. Our results are in accordance with recent papers: (i) Corn et al.¹⁸ demonstrated AZD7648-induced genotoxicity (translocations and kilobase-scale deletions in HSPCs), ii) Jasin et al.³⁰ observed extra-large LOHs (> 50 Mb) following PolQ/DNA-PKcs inhibition in mouse embryonic stem cells, and (iii) Kosicki et al.³⁸ reported kilobase-scale deletions in NHEJ-deficient mouse ES cells.

We now show that AZD7648 also increases MN and megabase-scale CN-LOH events, which remain stable from day 4 to day 14 in HSPCs. These LOHs persisted for up to two weeks in vitro in HSPCs and for up to three weeks in fibroblasts, without apparent selective disadvantage. Notably, such AZD7648 genotoxicity can induce a bias in editing outcome analysis based on short-read amplicon sequencing³⁹. This genotoxicity, linked to DNA repair pathway modulation by drugs, could be expected regarding their use in oncology to sensitize cancer cells to chemo/radiotherapies/PARP inhibitors. These treatments are known to induce a catastrophic genomic instability^{16,40–42}, demonstrating the critical role of NHEJ as a conservative mechanism that safeguards chromosomal integrity⁴³.

Where millions of edited cells are transplanted, even rare genotoxic events become a major safety issue. While recent studies^{8,12,19} have shown that aneuploid CAR-T cells harboring chromosomal rearrangements are gradually lost during culture or post-graft in mice and patients, it remains unclear whether HSPCs behave similarly or persist in vivo. Importantly, in our study, after editing HSPCs at the *HBG1/2p* loci, we found no evidence of rearranged edited cells persisting in vivo after 3-months engraftment in NSG mice, even when editing was performed with genotoxic AZD7648. DNA-PKcs is known to also function beyond NHEJ, including ribosomal RNA processing and hematopoiesis. In mice, kinase-dead DNA-PKcs combined with *TP53* loss leads to hemopathies⁴⁴. Here, transient DNA-PKcs inhibition prior transplantation did not impair HSPC engraftment or long-term hematopoietic differentiation. These data suggest that AZD7648-induced genotoxicity in chr11p can be lost in vivo but has to be carefully monitored. Very little is known about the fate of rearranged cells post-grafting. It is well-known that missegregated chromosomes often suffer during cytokinesis, triggering a DNA DSB response in daughter cells, involving ATM, Chk2, and p53, potentially leading to cell death⁴⁵. Further studies are needed to decipher the precise time-course of disappearance of these unwanted genomic by-products. It will be essential to determine if the in vivo loss results from (i) impaired graft capability, (ii) in vivo selective disadvantage of edited cells with genomic rearrangement, (iii) intrinsic protection of quiescent HSPCs ON-target genotoxicity, in accordance with G0/G1 protection. Whatever the underlying mechanisms, these in vivo results provide encouraging evidence supporting the safety of CRISPR-Cas9 nuclease protocols at least for the conditions tested.

Although we observed the disappearance of genotoxic events at long-term following *HBG1/2p* targeting in Chr11p, we cannot exclude that it is *locus* specific and that other chromosomal rearrangement could persist and potentially confer a selective advantage in vivo. Prevention of the initial occurrence of ON-target chromosomal genotoxicity is the best approach to propose safe CRISPR gene therapy. The best way to avoid genotoxicity is not to hope for its disappearance over time but rather to prevent its initial appearance. In this study, we also demonstrated the accuracy of scSNP-DNAseq to evaluate and

refine editing protocols, to mitigate ON-target genotoxicity. Thanks to this approach, we show that palbociclib, a CDK4/6 inhibitor, drastically lowers CRISPR-induced ON-target genotoxicity in HSPCs. We hypothesized that editing non-dividing HSPCs could bypass unintended genotoxicities associated with DSBs in dividing cells. Our data demonstrate that palbociclib results in less MN and in a sevenfold reduction in telomeric megabase-scale LOH, without impairing neither gene knockout efficiency by NHEJ nor cell graft capability. This preventing effect is in accordance with previous findings indicating that (i) MN and long deletions predominantly occur in dividing cells^{46–48}, that (ii) gene editing of quiescent HSPCs (without ex vivo culture) avoids genotoxicity²⁰, and (iii) gene editing of non-proliferating CAR-T editing is safer compared to proliferating T-cell¹².

We proposed that G0/G1 arrest during editing could impair genotoxicity by promoting end-joining after DSB. When palbociclib was combined with DNA-PKcs inhibition, to block NHEJ, genotoxicity mitigation was impaired, despite G0/G1 arrest, supporting the hypothesis that palbociclib may reinforce NHEJ repair pathway to preserve genomic stability. Altogether, these data highlight the central role of cell cycle in the regulation of ON-target genotoxicity, and underscore the utility of scDNA-seq for screening and optimizing safer genome editing protocols. In a future clinical projection, we evaluated palbociclib impact on long-term HSPCs function. Unexpectedly, palbociclib enhances HSPCs stemness phenotype and graft capability in non-edited cells. Further studies will be required to confirm this interesting effect in CRISPR-edited cells. Taken together, these results demonstrate the potential of palbociclib as a valuable strategy to mitigate CRISPR-Cas9 nuclease ON-target genotoxic risk for gene therapy.

Alternatively, new DSB-less CRISPR tools (e.g., base, prime, and click editors^{49–53}) have been proposed to minimize genotoxicity. However, recent studies reported unintended ON-target genotoxicity following base/prime editing in HSPCs^{54,55}. This suggests that scSNP-DNAseq, could also become an essential platform to assess the safety of the newer editing approaches.

Our custom panel enables sensitive detection and mapping of ON-target genotoxicity, particularly kilobase/megabase-scale rearrangements. This panel was designed to study two chromosomes (10 and 11), with approximately 400 amplicons containing SNPs analyzed at single-cell level. However, it does not provide a whole genome picture. Another team proposes a genome-wide approach, using a custom panel spanning all 24 chromosomes with one amplicon each 10 Mb. They detect whole-chromosome aneuploidies by CNV analysis (Mays et al.²³). However, this method lacks the resolution detection of aneuploidies in shorter regions, and copy-neutral genomic events. Nowadays, it is required to make a trade-off between sensitivity and genomic breadth analysis. Further optimizations of such panels combining local and whole genome coverage will allow the precise global analysis of genotoxicity. In this work, for bioinformatic analysis, we demonstrated that a focus approach using a small number of high-quality SNPs (five discriminant SNPs) outperforms global SNP analysis (UMAP) to detect megabase et kilobase LOH. Areas for future panel optimization include: (i) SNP pre-identification to choose only amplicons with SNPs truly present in the sample, (ii) improved amplicon pre-selection based on high PCR amplification efficiency (high total read counts) and (iii) expanding the panel size (current Tapestry technology allows up to 800 amplicons per cell, enabling broader coverage for both ON- and OFF-target genotoxicity detection, as proposed by Mays et al.²³).

Another limitation is cost. The microfluidics, library prep, and sequencing components of this technology are currently expensive, making it less accessible for routine use in academic laboratories. However, costs could be reduced by sample multiplexing, and this approach could be implemented in clinical gene therapy workflows for

pre- and post-graft quality control. In this context, the cost of safety monitoring must be weighed against the high expense of cell and gene therapies themselves.

In conclusion, our study demonstrates that multiplex single-cell approaches, and in particular custom SNP-based scDNA-seq, is a robust and sensitive tool that outperforms current methods, including scRNA-seq, for detecting at the single-cell level in primary cells in vitro and in vivo copy-loss and copy-neutral events. We identified frequent ON-target genotoxicity and chromosomal rearrangements post-editing, especially with AZD7648 and demonstrated that they can be mitigated by palbociclib exposure in vitro. Importantly, these rearrangements spontaneously disappear in vivo (targeting *HBG1/2p*) even with AZD7648 use. We propose MN (automatic quantification) and scSNP-DNAseq integration as a quality control step in (pre)clinical genome editing workflows. It could be both implemented before transplantation of CRISPR-Cas9-edited cells and post-graft, to monitor the long-term behavior of rearranged cells.

Methods

Cell culture

Human foreskin fibroblasts immortalized with hTERT (hFFs) were from ATCC® (CRL 4001, BJ-5ta). They were partially inactivated for *UROS* using a ribonucleoprotein (RNP) made of Cas9 protein complexed with a gRNA targeting *UROS* exon 4¹⁷. hFFs were maintained in DMEM, high-glucose (4.5 g.L⁻¹), L-Glutamine (1 g.L⁻¹) and pyruvate (Gibco® by Life-technologies™, Carlsbad, CA, USA, catalog n°31966047) supplemented with 10% fetal bovine serum (FBS) (Eurobio, Les Ulis, France, Catalog #CVFSVF00-01), 100 U/mL penicillin and 100 µg/mL streptomycin (Gibco® by Life-technologies™, Carlsbad, CA, USA; catalog #15070063), 10 µg/mL ciprofloxacin (Biogaran™, Colombes, France) and 0.5 µg/mL amphotericin B (Sigma-Aldrich®, Saint Louis, MO, USA, catalog #A2942).

Human CD34⁺ HSPCs were isolated from the cord blood. Briefly, mononuclear cells were isolated by Ficoll gradients. HSPCs were purified according to the manufacturer's instructions (hCD34-Positive Selection kit II, from Stem Cell Technologies, Vancouver, BC, Canada, catalog #17865), and purity was analyzed by flow cytometry using phycoerythrin (PE)-conjugated anti-CD34 antibody (clone 561, Biolegend, San Diego, CA, USA). The CD34⁺ cell purity was > 90%. Cryopreserved HSPCs were thawed and cultured in expansion medium consisting in StemSpan SFEM (Stem Cell Technologies, catalog #09600) supplemented with Flt3-L (100 ng/mL, catalog #GMP300-19-50UG), SCF (100 ng/mL, catalog #GMP300-07-50UG), hTPO (100 ng/mL, catalog #GMP300-18-50UG), (all from Peprotech, Cranbury, NJ, USA), 100 U/mL penicillin, and 100 µg/mL streptomycin (Gibco® by Life-technologies™, Carlsbad, CA, USA, catalog n°15070063), 10 µg/mL ciprofloxacin (Biogaran™, Colombes, France) and 0.5 µg/mL amphotericin B (Sigma-Aldrich®, Saint Louis, MO, USA, catalog n°A2942).

All cells were grown at 37 °C with 5% CO₂ levels. All cell lines were tested for mycoplasma.

To increase HDR, we added 3 “HDR boosters” in the medium for editing: NU7441 (2.5 µM, 18 h before transfection and for 2 days after transfection, from Selleckchem, Houston, US, catalog #S2638), AZD7648 (1 µM, 18 h before transfection and for 2 days after transfection, from MedChemExpress, Monmouth Junction, New Jersey, US, catalog #HY-111783) or XL413 (20 µM, for 2 days after transfection, no cell exposure performed before transfection, from Selleckchem, Houston, US, catalog #S7547). Dimethyl sulfoxide (DMSO, from Sigma-Aldrich®, Saint Louis, MO, USA, catalog #D2438), used to dissolve these compounds was used as a negative control. To prevent genotoxicity, cells were synchronized in G0/G1 phase by incubation with palbociclib (1 µM, Sigma Aldrich, Saint Louis, MO, USA, catalog #PZ0383) 18 h before and 24 h or 48 h (for scDNA-seq) after RNP transfection.

Editing tools

The crRNA for the *ABRAXAS2* and *UROS* targets (Ch10q) was designed using CHOP-CHOP software (chopchop.cbu.uib.no) (*ABRAXAS2* 5'-CCATCGAGTGGGAGGATCT-3' and *UROS* exon 4: 5'-GGAAGCAGCAGAGTTATGTT-3', Supplementary Table 1). The crRNA chosen for editing of the *HBG1* and *HBG2* promoters (Chr11p) is an already published gRNA (gRNA-68)²⁴. The different components of the CRISPR-Cas9 system were combined to form a RNP (all ordered at IDT, Integrated DNA Technologies, Coralville, IA, USA). For this, 17 µg of Alt-R® S.p. HiFi Cas9 Nuclease V3 when a ssODN was added (abbreviated hereafter as HiFiV3Cas9, Integrated DNA Technologies, Coralville, IA, USA, catalog #1081061) or Alt-R™ S.p. Cas9 Nuclease V3 (abbreviated hereafter as V3Cas9, Integrated DNA Technologies, Coralville, IA, USA, catalog #1081059) and 6.5 µM of sgRNA, were mixed and then incubated for 10–20 min at room temperature before electroporation. For HDR booster experiments, 6.5 µM of ssODN template was added (*ABRAXAS2* 5'-TCTGCTTCTTCATCCTAGTTCACCTACTTTGCCCCAGCTGCCTCCATCGAGTGGGAGGAAGAGCTCGACAGAGCCTGTTCACTCTAGTCATTTATGCAACAGACATCAATGGAACAT-3', and *UROS* 5'-CTGAAGATTACGGGGACTCATTTTTACCAGCCCAGAGCAGTGAAGCAGCAGAGCTCTGTTTAGAGCAAACAATAAACTGAAGGTGAGGGTG GGTCTGCTGTGGATTCCACTGGAC-3', Supplementary Table 2). Finally, 3.9 µM of Alt-R Cas9 Electroporation Enhancer solution (Integrated DNA Technologies, Coralville, IA, USA, catalog #1075916) was added to the RNP complex to improve electroporation efficiency.

Cells were transfected by electroporation using the Nucleofector 4D AMAXA electroporation system (Lonza®, Bale, Switzerland). In brief, 2.10⁵ to 3.10⁵ depending on the cell type (HSPCs and hFFs) were resuspended in P3 Primary Cell Line 4D-Nucleofector® (Lonza, Bale, Switzerland, catalog #V4XP-3024) and added to the RNP complex. Then cells were nucleofected using DO-100 and CZ-167 programs respectively.

Editing efficiency

Genomic DNA of edited cells, and their associated controls, was extracted using Nucleospin® Tissue (Macherey-Nagel®, Düren, Germany, catalog #740952.250) according to the manufacturer's protocol. The genomic region flanking the expected cut-site was amplified by PCR (HotStarTaq Plus DNA polymerase, Qiagen®, Venlo, Netherlands, catalog #203605) with adequate primers (*ABRAXAS2* targeting F: 5'-CCTGGCTCACTCACTCTGTG-3', R: 5'-AGGCCAGTTC AAACGCTCTT-3'; *UROS* targeting F: 5'-TAGTTCAGGCACATAG TAAGCAC-3', R: 5'-TCCCAAGGCAGAGTCTGTGA-3'; *HBG1/2* promoters targeting F: 5'-GCTTTGTTGCGCAGGTCAACATGTAT-3', R: 5'-GGGGCTGCTCTGCCTATGCAGTAGTC-3'), Supplementary Table 3. PCR products were purified with Nucleospin® Gel and PCR Clean-up (Macherey-Nagel®, Düren, Germany, catalog #740609.50S). Sanger sequencing was done on purified PCR products and sequenced by LIGHTRUN (GATC Biotech, Konstanz, Germany). Sanger sequencing data were analyzed using ICE v2 CRISPR Analysis tool (ICE) software (Synthego, Redwood City, CA, USA) and DecodR v3⁵⁶. Purified PCR products from unedited cells were used as control chromatograms.

To validate CRISPR-Cas9 efficiency at *HBG1/2p* in HSPCs, we used Nanopore NGS. Briefly, 7 days after editing, genomic DNA was extracted from cell pellets using Nucleospin® Tissue (Macherey-Nagel®, Düren, Germany, catalog #740952.250) according to the manufacturer's protocol. The genomic region flanking the edited site was amplified by Long Range PCR (LA Taq, Takara Bio, Kusatsu, Japan), with adequate primers. Sequencing library was prepared using Native Barcoding Kit 96 V14 (Oxford Nanopore Technologies, Oxford, United Kingdom, catalog #SQK-NBD114.96) according to the manufacturer's protocol. Sequencing was then performed using a MinION Mk1B device and a Flow Cell R10.4.1 (Oxford Nanopore Technologies, Oxford, United Kingdom, catalog #FLO-MIN114) to reach at least 3000 qualify-reads per sample (Q score > 9). After sequencing, super-

accurate base calling was performed using MinKNOW (v24.02.6) and fastq were aligned on human reference genome GrCH38 (GCA_0000001405.15) using a home-made Bash (v5.1.16) script based on Epi2Me (v5.1.9) wf-alignment pipeline (v1.1.2). Then, BAM were analyzed using a homemade bioinformatic pipeline in Python (v3.13.2) using pysam (0.22.0). Briefly, it classifies reads into categories (WT, small indels, 5 kb deletions, truncated etc...) based on CIGAR string interpretation. Results are summarized in.csv tables using pandas (v2.3.1). All scripts and documentation are available at: <https://github.com/BioGO-BRIC/HBG1-2---ONT-analysis>.

Micronuclei analysis by cytometry

The MicroFlow In Vitro-250/50 Kit (Litron Laboratories, Rochester, NY, USA, catalog #INVITRO250/50) was used for all MN assays, following the manufacturer's instructions. Briefly, cells were stained and lysed following the protocol described in the kit. Following harvest, a photo-activated dye Dye 1, Ethidium monoazide, was used to stain apoptotic and necrotic cells then the cells were washed. Subsequently, healthy chromatin was stained with the nucleic acid Dye 2, SYTOX Green. Cells could be stored up to 24 h at ambient temperature, protected from light, or refrigerated for up to 72 h, prior to analysis. Using a BD Accuri C6 Plus (BD Biosciences, Franklin Lakes, NJ, USA), flow cytometric analysis distinguished 10,000 to 20,000 real MN (SYTOX Green only) from nuclei, based on their weaker DNA-associated fluorescence signal. At least 10,000 cells per condition are analyzed.

MN analysis by nuclear fluorescent imaging

Cytogenetic examination was carried out on interphase nuclei on HSPCs after fixation by a solution of 3:1 methanol/glacial acetic acid fixative. DAPI (Sigma Aldrich, Saint Louis, MO, USA, catalog #MBD0015) staining was performed onto a microscopic slide and MN examination was evaluated under a fluorescent microscope Leica DM5500 B (Leica microsystem, Wetzlar, Germany) with the 63× objective lens (i.e., 630× magnification). The number of cells visualized for each condition is indicated in the legend of each figure. Blind count of MN with a medical cytogeneticist (J.T. in author list).

LOH analysis by FAMReD system (cytometry)

FAMReD is a cytometry-based system to detect induced LOHs in Chr10q with or without *TP53* inactivation¹⁷. On day 15 post-editing of hFFs *UROS*^{+/−}, 0.3 mM of 5-ALA (Sigma Aldrich, Saint Louis, MO, USA, catalog #A7793) were added to culture media. After 16 h of exposure (overnight), cells were washed twice with DPBS 1× (Gibco, by Life Technologies, Carlsbad, CA, USA, catalog #14190144) and put back in fresh media. Upon LOH, loss of *UROS* can be detected by the appearance of fluorescence due to porphyrin accumulation. Following 8 h of clearance, fluorescent cells were quantified by flow cytometry using a BD Accuri C6 Plus (BD Biosciences, Franklin Lakes, NJ, USA). UV-sensitive porphyrins were excited at 488 nm and the emitted wavelength was approximately 667 nm, detected by the PE-Cy5A PMT channel. FL-1 is a control green-fluorescent channel used to exclude auto-fluorescent cells. The system only detects 50% of the events when the cells become *UROS*^{−/−}. The true LOH rate is double.

Cell cycle

To evaluate impact of palbociclib and HDR boosters on hFFs and HSPCs cell cycle, cells were harvested and washed with DPBS (Gibco® by Life-technologiesTM, Carlsbad, CA, USA, catalog #14190144) with 2% FBS (Eurobio, Les Ulis, France, catalog #CVFSVF00-01) and EDTA 2 mM (Éthylènediamine-tétracétate disodium dihydrate, Euromedex, Souffelweyersheim, France, catalog #EU0007). Cells were fixed and permeabilized using the True-Nuclear Transcription Factor Buffer Set following the manufacturer's instructions. True-nuclear Fixation buffer (1×, from True-Nuclear Transcription Factor Buffer Set, 424401, Bio-Legend, San Diego, California, USA, catalog #424401) was added and

incubated for 45 min in the dark at ambient temperature. Subsequently, a true-nuclear 1× Perm Buffer (from the same set, BioLegend, San Diego, California, USA, catalog #424401) was used twice to wash. Cells were then stained with a PE mouse anti-Ki67 antibody (BD Biosciences, Franklin Lakes, NJ, USA, catalog #556027) for 30 min in the dark at ambient temperature and washed with true-nuclear 1× Perm Buffer (from the same set, BioLegend, San Diego, California, USA, catalog #424401). Pellet was harvested in DPBS with FBS 2% and EDTA 2 mM and resuspended in a 2 µg/mL Hoechst solution (bisBenzimide H 33342 trihydrochloride, Sigma-Aldrich®, Saint Louis, MO, USA, catalog B2261). Samples were stored at +4 °C overnight before analysis performed on a BD LSRFortessa™ Cell Analyzer (BD Biosciences, Franklin Lakes, NJ, USA). Data were analyzed with BD FACSDiva™ Software (BD Biosciences, Franklin Lakes, NJ, USA).

Design of custom Tapestry panel for sequencing

The panel comprises 403 probes mainly across the 10 & 11 human autosomes (Supplementary Table 1). To identify candidate target regions for the panel, we used the dbSNP (NCBI dbSNP Build 155, hg19) and considered only variant SNPs with a major allele frequency between >0.5 and <0.7 without discrepancy on certain ancestry group (e.g., global MAF = 0.5 and <0.5 in African and Caucasian ancestry in GnomAd v4). In Silico validation of the SNP design was assessed by testing it on the CORIELL (GIAB consortium, sample NAI2878, HG001) using bcftools (v1.18). The objective of >30% informative SNPs was largely achieved with 63%. All candidate SNPs were submitted to the Tapestry Panel Designer to generate a panel design and ensured that the designed probes targeted the candidate SNPs and had similar GC contents. Support for the custom panel design and synthesis of the panel was provided by Mission Bio using v3 Tapestry Chemistry (Mission Bio, South San Francisco, CA, USA).

Single-cell DNA-seq

Single-cell DNA-seq was performed using the Tapestry platform (Mission Bio, South San Francisco, CA, USA) according to the manufacturer's specifications with kit v3. Briefly, cryopreserved human cells were gently thawed, washed, and quantified using a Countess II cell counter (ThermoFisher Scientific, Waltham, MA, USA). The cells were then diluted to a concentration of 2000 to 3000 cells per µL in the cell buffer. Next, 35 µL of cell suspension was loaded onto a microfluidics cartridge and cells were encapsulated on the Tapestry instrument, followed by cell lysis with protease digestion, followed by heat inactivation using a thermal cycler. The cell lysate was reintroduced into the cartridge and processed such that each cell possessed a unique molecular barcode. Amplification of the custom-targeted DNA regions was carried out by incubating the barcoded DNA emulsions in a thermocycler following Mission Bio's specifications. Emulsions were broken, DNA digested and purified with AMPure XP beads (Beckman Coulter, Brea, CA, USA, catalog #A63881). The beads were pelleted and washed and DNA libraries were generated. Final libraries were purified with AMPure XP beads. All libraries were sized and quantified using an Agilent Fragment Analyzer and pooled for sequencing on an Illumina NovaSeq6000 S1 flow cell with 2 × 150 bp at Gustave Roussy. A summary of metrics (mean reads/cell/amplicon, reads mapped to target, dropout rate, and amplicon >10×) are provided in Supplementary Table 4. Raw data for each run and sample are available in data availability section (Zenodo and NCBI SRA database).

Tapestry single cell DNA analysis

Single-cell DNA sequencing data were obtained from primary cells and analyzed using the Tapestry Mosaic pipeline and customized versions of Mission Bio's available Jupyter notebook (Mission Bio, San Francisco, CA, USA). Quality control steps included the removal of low-quality or missing genotype cells as per the pipeline's automated

filters. Variants were annotated using the default settings provided by the manufacturer in the Tapestry Mosaic suit.

For HSPCs edited in *HBG1/2* promoters, clustering method using PCA and UMAP, based on 88 heterozygous SNPs on chromosome 11 (Chr11), was performed. To look for genome rearrangements, we performed a dimensionality reduction using PCA and Uniform manifold approximation and projection (UMAP) for non-linear embedding. Clustering was performed using hierarchical density-based spatial clustering of applications with noise (HDBSCAN) with a minimum cluster size of 22, enabling the identification of distinct genomic sub-populations. The optimal number of principal components (PCs) was determined through an elbow plot analysis, identifying the inflection point where the explained variance ratio begins to plateau. This transition, occurring around 8 PCs (determined via visual inspection), represents the balance between maximizing data variance retention and minimizing noise contribution. UMAP were then generated using the selected PCs as input, employing the Euclidean distance metric with default Tapestry Mosaic parameters. Clustering was carried out in an unsupervised manner using the *hdbscan* algorithm.

In case of selection of 5 high-quality SNPs, variant annotation manufacturer settings were not modified. LOHs analysis was performed by adjusting the max ADO score at 0.2 and the Minimum clone size at 0.01. Only heterozygous SNPs ($0.40 < AF < 0.60$) present in at least 60% of the cells were retained.

SNP profiles to cluster cells were retained if they contained at least 6 cells. The CNVs analysis was only performed in the LOH subtypes with at least 6 cells. The filters were set up to 50 for amplicon completeness, 10 for amplicon read depth, and 10 for mean cell read depth. CNVs were inferred from single-cell amplicon read-depth data using the Mission Bio Mosaic pipeline. Ploidy was calculated for each cell and each amplicon by normalizing read counts against the mean of the "normal" cell population, which was designated as the diploid reference (considering ploidy 2 for normal cells, without LOH). LOH ploidy was calculated by averaging the ploidies obtained for amplicons encompassing the LOH. scDNAseq Global Metrics are available in Supplementary Table 4.

Proliferation, cell death, in vitro phenotype and stemness gene expression in HSPCs. Proliferation was assessed with sequential cell numeration following or not 36-h exposure to Palbociclib. Cell numerations were performed using KOVA slides 10 counting chambers (Alltrista Plastics Ltd., USA; distributed by Labellians, France, Ref. 87144 F) according to the manufacturer's instructions.

Apoptosis was detected by staining the cells with anti-human APC Annexin V (#640920 Biolegend, San Diego, CA, USA) and propidium iodide (#596552, Dutscher) solution followed by flow cytometry analysis. Cells that were propidium iodide (PI) negative and Annexin V negative were considered healthy, cells, PI negative and Annexin V positive cells were considered apoptotic, and cells that were positive to both PI and Annexin V considered necrotic.

To evaluate phenotype (stemness) of HSPCs, cells were stained with human FITC anti-CD38, and human PEcy7C anti-CD90 antibodies, from BD Biosciences (respectively #567148 and #561558, BD Biosciences, Franklin Lakes, NJ, USA) human PE anti-CD34 and human APC anti-CD133 from Biolegend (respectively #343506 and #372806, Biolegend, San Diego, CA, USA), and analyzed by cytometry using FACS Canto II from BD.

Stemness Hematopoietic gene expression was evaluated by RTqPCR. Total RNAs were extracted using NucleoSpin RNA Plus XS Microkit (Macherey-Nagel®, Düren, Germany). mRNAs were reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Life Technologies Corporation, Carlsbad, California, USA). In all cases, qPCR was performed using Go Taq® qPCR Master Mix (Promega, Fitchburg, Wisconsin, USA) in a CFX96™ Real-Time System (Bio-Rad Laboratories, Hercules, California, USA).

Primers were synthesized by Eurogentec (Liège, Belgium). Previously published primers⁵⁷ were used.

Hematopoietic engraftment in immunodeficient mice

NSG mice were obtained from the Jackson Laboratory and bred in-house (animal facilities, University of Bordeaux). Female mice between 8 and 10 weeks old were used for all experiments. The accommodation conditions are maintained at a temperature of $21^{\circ}\text{C} \pm 1.5^{\circ}\text{C}$, with standard 12-h cycles and humidity levels between 40 and 65%. Prior to cell injection, mice were conditioned by two intra-peritoneal injections of 20 mg/kg busulfan (Busulfan; Fresenius Kabi), at 24 h intervals. Two days after the second injection of busulfan, unmanipulated and treated hCD34⁺ cells were IV-injected into recipient mice under anesthesia (Isoflurane, 5% at initiation then 2.5%). Depending on our objectives, mice were sacrificed at different time points (weeks) after transplantation, and BM was harvested from femurs. Total BM cells were labelled with BV421 anti-murine TER119 (BD, 740686), BV421 anti-murine CD71 (BD, 740667), BV421 anti-murine CD45 (BD, 563890) to exclude murine cells from the analysis. FITC anti-human CD45 (Beckman Coulter, A07782), PE anti-human CD19 (Beckman Coulter, A07782), and APC anti-human CD33 (Beckman Coulter, A07782) antibodies. Human vs. mouse chimerism was analyzed by flow cytometry with FACS Canto II.

Palbociclib effect

For limiting dilution assay (LDA) with or without palbociclib, ten mice per group (cell dose) received 25, 50, 100, 500, or 3000 CD34⁺ cells non-treated or treated with palbociclib. Mice were sacrificed 17 weeks after transplantation and their BM analyzed by flow cytometry as mentioned above. SRC frequencies with 95% IC were determined using the extreme limiting dilution analysis webtool accessible at <http://bioinf.wehi.edu.au/software/elda/>. For secondary transplantation, to evaluate a potential effect of palbociclib on long-term SRC, 3000 non-treated or treated CD34⁺ cells were injected in primary mice (10 mice per group). Eight weeks after transplantation, mice were sacrificed, and BM was harvested from femurs. The total cells from one femur of each primary mouse was suspended in 20 μL of StemSpan SFEM II medium (StemCell Technologies) and then injected directly in the BM of one respective secondary recipient by intra-bone injection. Mice were sacrificed 17 weeks after transplantation and their BM analyzed by flow cytometry as mentioned above.

For Fig. 6c, in order to test palbociclib function on engraftment, 5 mice per group received 10,000 CD34⁺ cells treated or not with palbociclib ($n = 2$ independent experiments). For Fig. 6h, 5 mice per group received 50000 cells, edited or not in *ABRAXAS2* by *CRISPR-Cas9*, with or without palbociclib ($n = 2$ independent experiments). Mice were sacrificed 17 weeks after transplantation and their BM analyzed by flow cytometry as mentioned above.

Long-term in vivo genotoxicity monitoring (with or without AZD7648)

To assess the potential genotoxicity of *HBG1/2p*-CRISPR editing on CD34⁺ cells, 400,000 CD34⁺ edited without or with AZD7648 were injected intravenously into recipient mice (2 mice per group). 90 days later, the mice were sacrificed, and the whole BM cells from femurs and tibias were harvested prior to human CD45⁺ cell selection by magnetic beads (Miltenyi Biotech, hCD45 microbeads) and scSNP-DNAseq experiment.

Statistical analysis and reproducibility

When possible, experiments were conducted at least 3 times independently. No statistical method was used to predetermine sample size. No data were excluded from the analyses. The experiments were not randomized. The Investigators were not blinded to allocation

during experiments and outcome assessment. Only DAPI analysis of MN was performed blindly. Statistical significance was inferred when necessary. Exact distinct and independent experiments size is indicated in each legend (n). GraphPad Prism 10 software (GraphPad, Boston, MA, USA) was used for statistical analysis. Results are presented as mean \pm SD, frequencies, or mean \pm SEM (indicated in each figure legend). The parametric T test (two-sided) was used when distribution was Gaussian/normal (Shapiro–Wilk test). The non-parametric Mann–Whitney test (one-sided) was used to compare two groups when distribution was not normal. One-way ANOVA (two-sided), complemented with the unprotected Fisher's Least Significant Difference test, was used to compare more than two groups. Percentages of LOHs in HSPCs were compared by the Chi-square test.

Ethics statement

Our research complies with all relevant ethical regulations. Cord blood Human CD34⁺ HSPCs were obtained in collaboration with EFS Nouvelle Aquitaine-Limousin (24SPL 02 agreement for the cessation of between EFS and Bordeaux University), according to the hospital's ethical institutional review board and with the mother's informed consent. Prior to donating peripheral blood, each donor read an informative document and completed a questionnaire allowing the possibility to be opposed to the use of discarded cells for research.

The animal experiments presented in this paper were authorized by the Ethical Committee of Gironde (CEEA50, 2022/06/03), France (ref. APAFIS #35068-2022013110253304 v8). All animal experiments were performed in agreement with French regulation—licenses granted to C.D. and P.B.G. through numbers. 33 07 010 and A33 12 054, respectively.”

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

Source data are provided with this paper. The source data generated in this study have been deposited in the ZENODO database <https://doi.org/10.5281/zenodo.17256630>. FASTQ files of Single cell DNA sequencing and Long read nanopore. Minion and scDNA sequencing data are available on NCBI SRA database, reference [PRJNA1370658](https://doi.org/10.5281/zenodo.17601950).

Code availability

The source code is available on GitHub under the Creative Commons Zero v1.0 Universal License (CCO 1.0): <https://github.com/BioGO-BRIC/HBG1-2---ONT-analysis>, and archived on Zenodo with the <https://doi.org/10.5281/zenodo.17601950>.

References

1. Rouet, P., Smih, F. & Jasin, M. Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. *Proc. Natl. Acad. Sci. USA* **91**, 6064–6068 (1994).
2. Jasin, M. & Haber, J. E. The democratization of gene editing: insights from site-specific cleavage and double-strand break repair. *DNA Repair* **44**, 6–16 (2016).
3. Doudna, J. A. & Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. *Science* **346**, 1258096 (2014).
4. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**, 819–823 (2013).
5. Kosicki, M., Tomberg, K. & Bradley, A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. *Nat. Biotechnol.* **36**, 765–771 (2018).
6. Cullot, G. et al. CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations. *Nat. Commun.* **10**, 1136 (2019).

7. Boutin, J. et al. CRISPR-Cas9 globin editing can induce megabase-scale copy-neutral losses of heterozygosity in hematopoietic cells. *Nat. Commun.* **12**, 4922 (2021).
8. Nahmad, A. D. et al. Frequent aneuploidy in primary human T cells after CRISPR-Cas9 cleavage. *Nat. Biotechnol.* **40**, 1807–1813 (2022).
9. Leibowitz, M. L. et al. Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing. *Nat. Genet.* **53**, 895–905 (2021).
10. Papanthasiou, S. et al. Whole chromosome loss and genomic instability in mouse embryos after CRISPR-Cas9 genome editing. *Nat. Commun.* **12**, 5855 (2021).
11. Boutin, J. et al. ON-target adverse events of CRISPR-Cas9 nuclease: more chaotic than expected. *CRISPR J.* **5**, 19–30 (2022).
12. Tsuchida, C. A. et al. Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. *Cell* **186**, 4567–4582.e20 (2023).
13. Alanis-Lobato, G. et al. Frequent loss of heterozygosity in CRISPR-Cas9-edited early human embryos. *Proc. Natl. Acad. Sci. USA* **118**, e2004832117 (2021).
14. Zuccaro, M. V. et al. Allele-specific chromosome removal after Cas9 cleavage in human embryos. *Cell* **183**, 1650–1664 (2020).
15. Schioli, G. et al. Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response. *Cell Stem Cell* **24**, 551–565 (2019).
16. Fok, J. H. L. et al. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. *Nat. Commun.* **10**, 5065 (2019).
17. Cullot, G. et al. Cell cycle arrest and p53 prevent ON-target megabase-scale rearrangements induced by CRISPR-Cas9. *Nat. Commun.* **10**, 4072 (2023).
18. Cullot, G. et al. Genome editing with the HDR-enhancing DNA-PKcs inhibitor AZD7648 causes large-scale genomic alterations. *Nat. Biotechnol.* **43**, 1778–1782 (2025).
19. Stadtmayer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. *Science* **367**, eaba7365 (2020).
20. Zeng, J. et al. Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells. *Cell Stem Cell* **32**, 191–208.e11 (2025).
21. Ruff, D. W. et al. High-throughput multimodal single-cell targeted DNA and surface protein analysis using the Mission Bio Tapestry platform. *Methods Mol. Biol.* **2386**, 171–188 (2022).
22. Borsi, E. et al. Single-cell DNA sequencing reveals an evolutionary pattern of CHIP in transplant eligible multiple myeloma patients. *Cells* **13**, 657 (2024).
23. Mays, J. C. et al. KaryoTap enables aneuploidy detection in thousands of single human cells. Preprint at *bioRxiv* <https://doi.org/10.1101/2023.09.08.555746> (2024).
24. Sharma, A. et al. CRISPR-Cas9 editing of the HBG1 and HBG2 promoters to treat sickle cell disease. *N. Engl. J. Med.* **389**, 820–832 (2021).
25. Kalter, N. et al. Precise measurement of CRISPR genome editing outcomes through single-cell DNA sequencing. *Mol. Ther. Methods Clin. Dev.* **33**, 101449 (2025).
26. Antoniani, C., Meneghini, V. & Lattanzi, A. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β -globin locus. *Blood* **131**, 1960–1973 (2018).
27. Davis, L. et al. POLQ suppresses interhomolog recombination and loss of heterozygosity at targeted DNA breaks. *Proc. Natl. Acad. Sci. USA* **117**, 22900–22909 (2020).
28. Dutta, A. & Schacherer, J. The dynamics of loss of heterozygosity events in genomes. *EMBO Rep.* **26**, 602–612 (2025).
29. Regan, S. B. et al. Megabase-scale loss of heterozygosity provoked by CRISPR-Cas9 DNA double-strand breaks. *Mol Cell* **85**, 4119–4137.e10 (2025).
30. Wienert, B. et al. Timed inhibition of CDC7 increases CRISPR-Cas9 mediated templated repair. *Nat. Commun.* **11**, 2109 (2020).
31. Wimberger, S. et al. Simultaneous inhibition of DNA-PK and Pol θ improves integration efficiency and precision of genome editing. *Nat. Commun.* **14**, 4761 (2023).
32. Cloarec-Ung, F. M. et al. Near-perfect precise on-target editing of human hematopoietic stem and progenitor cells. *Elife* **12**, RP91288 (2024).
33. Robert, F. et al. Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing. *Genome Med.* **7**, 93 (2015).
34. Selvaraj, S. et al. High-efficiency transgene integration by homology-directed repair in human primary cells using DNA-PKcs inhibition. *Nat. Biotechnol.* **42**, 731–744 (2024).
35. Stack, J. T. et al. DNA-PKcs inhibition improves sequential gene insertion of the full-length CFTR cDNA in airway stem cells. *Mol. Ther. Nucleic Acids* **35**, 102339 (2024).
36. White, N. et al. Unveiling the cut-and-repair cycle of designer nucleases in human stem and T cells via CLEAR-time dPCR. *Nat. Commun.* **16**, 9571 (2025).
37. Podrimaj-Bytyqi, A. et al. The frequencies of micronuclei, nucleoplasmic bridges and nuclear buds as biomarkers of genomic instability in patients with urothelial cell carcinoma. *Sci. Rep.* **8**, 17873 (2018).
38. Kosicki, M. et al. Cas9-induced large deletions and small indels are controlled in a convergent fashion. *Nat. Commun.* **13**, 3422 (2022).
39. Aussel, C., Cathomen, T. & Fuster-Garcia, C. The hidden risks of CRISPR/Cas: structural variations and genome integrity. *Nat. Commun.* **16**, 7208 (2025).
40. Laroche-Clary, A. et al. Selective DNA-PK inhibition enhances chemotherapy and ionizing radiation activity in soft-tissue sarcomas. *Clin. Cancer Res.* **30**, 629–637 (2024).
41. Deng, L. et al. Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening. *Cell Death Discov.* **9**, 40 (2023).
42. Liu, S. et al. CDC7 inhibition potentiates antitumor efficacy of PARP inhibitor in advanced ovarian cancer. *Adv. Sci. (Weinh.)* **11**, e2403782 (2024).
43. Wang, J., Sadeghi, C. A. & Frock, R. L. DNA-PKcs suppresses illegitimate chromosome rearrangements. *Nucleic Acids Res.* **52**, 5048–5066 (2024).
44. Shao, Z. et al. DNA-PKcs has KU-dependent function in rRNA processing and haematopoiesis. *Nature* **579**, 291–296 (2020).
45. Janssen, A. et al. Chromosome segregation errors as a cause of DNA damage and structural chromosome aberrations. *Science* **333**, 1895–1898 (2011).
46. Heddle, J. A. & Carrano, A. V. The DNA content of micronuclei induced in mouse bone marrow by g-irradiation: evidence that micronuclei arise from acentric chromosomal fragments. *Mutat. Res.* **44**, 63–69 (1977).
47. Liu, S. & Pellman, D. The coordination of nuclear envelope assembly and chromosome segregation in metazoans. *Nucleus* **11**, 35–52 (2020).
48. Hustedt, N. & Durocher, D. The control of DNA repair by the cell cycle. *Nat. Cell Biol.* **19**, 1–9 (2016).
49. Komor, A. C. et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature* **533**, 420–424 (2016).
50. Gaudelli, N. M. et al. Programmable base editing of A T to G C in genomic DNA without DNA cleavage. *Nature* **551**, 464–471 (2017).
51. Rees, H. A. & Liu, D. R. Base editing: precision chemistry on the genome and transcriptome of living cells. *Nat. Rev. Genet.* **19**, 770–788 (2018).
52. Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. *Nature* **576**, 149–157 (2019).
53. Ferreira da Silva, J. et al. Click editing enables programmable genome writing using DNA polymerases and HUH endonucleases. *Nat. Biotechnol.* **43**, 923–935 (2025).

54. Fiumara, M. et al. Genotoxic effects of base and prime editing in human hematopoietic stem cells. *Nat. Biotechnol.* **42**, 877–891 (2024).
55. Huang, M. E. et al. C-to-G editing generates double-strand breaks causing deletion, transversion and translocation. *Nat. Cell Biol.* **26**, 294–304 (2024).
56. Bloh, K. et al. Deconvolution of complex DNA repair (DECODR): establishing a novel deconvolution algorithm for comprehensive analysis of CRISPR-edited Sanger sequencing data. *CRISPR J.* **4**, 120–131 (2021).
57. Charaf, L. et al. Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells. *Leukemia* **31**, 65–74 (2017).

Acknowledgements

Tapestri equipments from Mission Bio were acquired at Gustave Roussy Institute thanks to MyProbe ANR-17-RHUS-0008 (N.D.). This work was supported by the French national research agency (A.N.R.) (grants ANR-21-CE18-0002 (A.B.) and ANR-PRME-23-CE52 (F.M.G.)), by Agence de Biomédecine (A.B.), and by la Fondation pour la Recherche Médicale (FRM, grant EQU202403018062, F.M.G.). C.B. was supported by funding from INSERM (Poste accueil INSERM). C.T. is supported by AFM telethon (#24581). We thank Ivan Lukic and Stephane Collinet from Mission Bio for their advice and technical support for Mission Bio software. We thank Zoran Ivanovic, research director at Etablissement Francais du Sang (Aquitaine, France), for his valuable advice concerning hematopoietic stem cell in vivo assays. We thank the FACSility cytometry platform at Bordeaux University (TBMCore, Bordeaux, France). We thank INSERM Transfert for valorization assistance. We thank Sandrine Hamon, Patrice Dutrinus, and Stephanie Lannelongue for administrative assistance and financial management.

Author contributions

V.M., S.F., C.B., J.B., A.B., F.M.G. design, analysis of data, and drafting of the manuscript. I.L.-G., S.F., M.R., C.B.: cell culture, CRISPR editing, FACS experiments. C.B., C.T., V.M., S.F.: nanopore sequencing, RTqPCR, and bioinformatic analysis; N.D., M.F.: scDNA-seq experiments. A.P.: cell cycle protocol development. V.M., J.B.: scDNA seq bioinformatics analysis; J.T., J.B.: FISH experiments. P.B.G., C.D., J.B.: animal study design and experiments. S.D., J.B., D.C.: helpful discussion and revision of the manuscript. A.B., F.M.G.: supervision, funding acquisition, analyzing data, writing the manuscript, and final approval of the manuscript. All authors edited and approved the final manuscript.

Competing interests

S.F., A.B., and F.M.G. declared a patent application EP23305760 filed on May 13th 2023 and claims the use of palbociclib to prevent genotoxicity induced by nuclease. The remaining authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41467-025-68177-3>.

Correspondence and requests for materials should be addressed to François Moreau-Gaudry or Aurélie Bedel.

Peer review information *Nature Communications* thanks Teresa Davoli and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2026